CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Bill Sibold

President and Chief Executive Officer, Madrigal Pharmaceuticals, Inc.

Search every verified Bill Sibold interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Bill Sibold, President and Chief Executive Officer of Madrigal Pharmaceuticals, has discussed the company's progress with its MASH treatment drug, Rezdiffra, in multiple media appearances. He described the drug's launch as the best he has been associated with in his career, noting that the company exceeded $100 million in sales in its third quarter of launch and reported over 23,000 patients on the drug as of its last quarterly call. Sibold stated that the company is at roughly 7% penetration into the diagnosed patient population of 315,000, and he emphasized the potential for long-term growth, saying the company is positioned for "decades of growth" in a market he described as having high unmet need. Sibold has also addressed competition in the MASH and GLP-1 treatment spaces. He characterized the entry of larger companies into the market as helpful for driving awareness and diagnosis, and he expressed confidence in Madrigal's ability to compete, citing the company's product profile and experienced team. Regarding a licensed oral GLP-1 drug, he explained that the company aims for a combination approach with Rezdiffra, focusing on safety and tolerability rather than pursuing the highest weight loss. He also discussed payer coverage, stating that the company achieved its goal of 80% commercial coverage by the end of 2024, and he noted ongoing efforts to work with payers and patient associations to ensure access.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →